ClinConnect ClinConnect Logo
Search / Trial NCT05443906

Home Exercise for Individuals with Neurodegenerative Disease

Launched by HUGO W. MOSER RESEARCH INSTITUTE AT KENNEDY KRIEGER, INC. · Jul 1, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, called "Home Exercise for Individuals With Neurodegenerative Disease," is looking at how targeted exercise programs can help improve walking for people with certain neurodegenerative diseases. These include conditions like leukodystrophy, ataxia, and other similar disorders that affect movement. The study aims to recruit individuals aged 18 to 39 years, regardless of gender, who have specific types of conditions, such as X-linked adrenoleukodystrophy or confirmed genetic mutations related to their diagnosis.

Participants in the trial will engage in home exercises designed to enhance their mobility. To be eligible, individuals must be able to stand without support for 30 seconds and walk for 2 minutes, possibly using a cane or walker. However, those with certain uncontrolled medical conditions or severe cognitive issues may not qualify. This study is important as it seeks to find effective ways to help improve the quality of life for those dealing with these challenging diseases through targeted exercise interventions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • The eligibility criteria for males is X-linked adrenoleukodystrophy as determined by biochemical determination or genetic testing.
  • The eligibility criteria for females is X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis.
  • The Leukoenceophalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion is a confirmed DARS2 mutation through genetic analysis.
  • For people with cerebellar ataxia, people with diagnoses of cerebellar damage from stroke, tumor or degeneration will be included. Those with a genetically confirmed cerebellar disorder will be asked to provide their genetic testing to note their particular type of ataxia.
  • We will also include patients with other neurodegenerative diseases similar to these disorders as determined by chart review and clinical exam.
  • Healthy Volunteers
  • Able to stand for 30 seconds without upper extremity support
  • Ambulatory (including use of a cane or a walker)
  • Able to walk for 2 minutes
  • Exclusion Criteria:
  • * Other medical or psychological conditions which in the clinical judgement of the investigator would interfere with acquiring the study information or performing the exercises safely including but not limited to:
  • Uncontrolled hypertension, orthopedic conditions, diabetes, seizure disorder, peripheral vestibular loss, severe aphasia, dementia, pregnancy

About Hugo W. Moser Research Institute At Kennedy Krieger, Inc.

The Hugo W. Moser Research Institute at Kennedy Krieger, Inc. is a leading research institution dedicated to advancing the understanding and treatment of neurodevelopmental disorders. With a strong focus on innovative scientific research, the Institute fosters collaboration among experts in various fields, including neuroscience, genetics, and rehabilitation. By conducting rigorous clinical trials and studies, the Institute aims to translate findings into effective interventions that improve the quality of life for individuals with disabilities. Its commitment to excellence in research and patient care positions it as a pivotal player in the advancement of pediatric healthcare and therapeutic solutions.

Locations

Baltimore, Maryland, United States

Patients applied

0 patients applied

Trial Officials

Jennifer Keller, PT

Principal Investigator

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials